Viking stock surges 39.5% on maintenance data release
1 Sep 22 7:19 AM · 1d ago · 7 articles · 2 sources · development 1 of 1
VKTX surged 39.5% in pre-open trading, sending shares to $42 and approaching its 52-week high of $43.15, driven entirely by company-specific news rather than broader market movement.
“In the 12-week maintenance phase, every-other-week dosing preserved up to 97% of prior weight loss and monthly dosing up to 90%, compared with 61% for placebo.”
Viking Therapeutics, Company announcement · rss ↗Viking Therapeutics Clinical-stage biopharmaceutical companyEli Lilly Obesity drug competitorNovo Nordisk Obesity drug competitorOppenheimer Equity research analyst
The whole story articles the bright band is this development · numbered dots are the others · click one to jump
Reported in the same hours no headline names this development itself — these 1 claim were published in its stretch
-
first by Investor's Business Daily, 1d ago · also Seeking Alpha, Investing.com News, Barron's, Moomoo
5 more headlines
- Viking Therapeutics soars after trial data for obesity drug Seeking Alpha · 1d ago
- Why is Viking Therapeutics stock surging today? Investing.com · 1d ago
- Viking Therapeutics Stock Surges 26% After Weight-Loss Drug Trial Barron's · 1d ago
- Viking Therapeutics stock soars on obesity data (VKTX:NASDAQ) Seeking Alpha · 1d ago
- Viking Therapeutics Stock Surges 36%+ Intraday. It Could Challenge Lilly and Novo's Obesity Empire Moomoo · 1d ago
All 1 developments of Viking Therapeutics soars 39.5% on obesity drug maintenance… →
NewswiresGoogle News